B Zinman1. Show Affiliations » 1. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Medicine, University of Toronto, Canada.
Abstract
Entities: Disease
Mesh: See more » Cost-Benefit AnalysisDiabetes Mellitus, Type 1/drug therapyDiabetes Mellitus, Type 1/economicsHumansHypoglycemic Agents/economicsHypoglycemic Agents/therapeutic useInsulin/economicsInsulin/therapeutic usePatient Care TeamRandomized Controlled Trials as Topic
Substances: See more » Hypoglycemic AgentsInsulin
Year: 1997 PMID: 9248707 DOI: 10.1007/s001250051414
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122